105 related articles for article (PubMed ID: 28328042)
1. Pathologic Predictors of Treatment Response to Neo-adjuvant Chemotherapy for Invasive Lobular Breast Carcinoma.
Tsai M; Finkelstein M; Lillemoe T; Susnik B; Grimm E; Kang SH; Kelly C; Swenson K
Breast J; 2017 Sep; 23(5):607-609. PubMed ID: 28328042
[No Abstract] [Full Text] [Related]
2. Does neoadjuvant/adjuvant chemotherapy change the natural history of classic invasive lobular carcinoma?
Katz A
J Clin Oncol; 2005 Sep; 23(27):6796; author reply 6796-7. PubMed ID: 16170189
[No Abstract] [Full Text] [Related]
3. Pathologic tumor response of invasive lobular carcinoma to neo-adjuvant chemotherapy.
Joh JE; Esposito NN; Kiluk JV; Laronga C; Khakpour N; Soliman H; Catherine Lee M
Breast J; 2012; 18(6):569-74. PubMed ID: 23034096
[TBL] [Abstract][Full Text] [Related]
4. [Clinical and morphological features and treatment for lobular breast cancer].
Tabagua TT; Semiglazov VV; Bus'ko EA; Semiglazova TIu; Voroshnikov VV
Vopr Onkol; 2013; 59(3):386-9. PubMed ID: 23909043
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients.
Croshaw R; Shapiro-Wright H; Svensson E; Erb K; Julian T
Ann Surg Oncol; 2011 Oct; 18(11):3160-3. PubMed ID: 21947594
[TBL] [Abstract][Full Text] [Related]
6. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
7. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
8. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
[TBL] [Abstract][Full Text] [Related]
9. What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?
Maltoni R; Bravaccini S
Breast Cancer Res Treat; 2019 Aug; 177(1):231-232. PubMed ID: 31119566
[No Abstract] [Full Text] [Related]
10. Primary systemic chemotherapy of invasive lobular carcinoma of the breast.
Katz A; Saad ED; Porter P; Pusztai L
Lancet Oncol; 2007 Jan; 8(1):55-62. PubMed ID: 17196511
[TBL] [Abstract][Full Text] [Related]
11. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
Sullivan PS; Apple SK
Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
[TBL] [Abstract][Full Text] [Related]
12. Metaplastic carcinoma of the breast.
Okada N; Hasebe T; Iwasaki M; Tamura N; Akashi-Tanaka S; Hojo T; Shibata T; Sasajima Y; Kanai Y; Kinoshita T
Hum Pathol; 2010 Jul; 41(7):960-70. PubMed ID: 20236684
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.
Peintinger F; Kuerer HM; Anderson K; Boughey JC; Meric-Bernstam F; Singletary SE; Hunt KK; Whitman GJ; Stephens T; Buzdar AU; Green MC; Symmans WF
Ann Surg Oncol; 2006 Nov; 13(11):1443-9. PubMed ID: 17028770
[TBL] [Abstract][Full Text] [Related]
14. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
15. Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact?
Soucy G; Bélanger J; Leblanc G; Sideris L; Drolet P; Mitchell A; Leclerc YE; Dufresne MP; Beaudet J; Dubé P
J Am Coll Surg; 2008 Jun; 206(6):1116-21. PubMed ID: 18501808
[TBL] [Abstract][Full Text] [Related]
16. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
17. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy.
Goldstein NS; Decker D; Severson D; Schell S; Vicini F; Margolis J; Dekhne NS
Cancer; 2007 Oct; 110(8):1687-96. PubMed ID: 17722109
[TBL] [Abstract][Full Text] [Related]
18. [Response evaluation with mammography and ultrasound].
Junkermann H; Schmid H; Sinn HP; Wallwiener D
Zentralbl Gynakol; 1996; 118(10):572-3. PubMed ID: 8999712
[No Abstract] [Full Text] [Related]
19. [Primary systemic therapy in breast cancer patients (2007-2010)].
Zapf I; Tizedes G; Pavlovics G; Kovács G; Kálmán E; Szalai G; Kövér E; Farkas R; Horváth OP
Magy Seb; 2011 Oct; 64(5):223-8. PubMed ID: 21997525
[TBL] [Abstract][Full Text] [Related]
20. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
